Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer
Uddalak Bharadwaj(The University of Texas MD Anderson Cancer Center), David J. Tweardy(The University of Texas MD Anderson Cancer Center), Bhuvanesh Dave(University Hospital Galway), Judy C. Chang(Center for Human Genetics), Ammar Adam(Baylor College of Medicine), Moses M. Kasembeli(The University of Texas MD Anderson Cancer Center), David Torres(Baylor College of Medicine), Michael T. Lewis(Baylor College of Medicine), Wenjie Wei(Baylor College of Medicine), Lacey E. Dobrolecki(Baylor College of Medicine), Chad J. Creighton(Baylor College of Medicine), T. Kris Eckols(Baylor College of Medicine), Michael A. Mancini(Baylor College of Medicine), Melissa D. Landis(Baylor College of Medicine), Mikhail Kolosov(Baylor College of Medicine), X. Zhang(Baylor College of Medicine)
Cited by 159
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k